

Appl. No. 09/889,300

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A pharmaceutical composition for treatment of cancer disease comprising a first antibody directed against the cellular membrane antigen Ep-CAM and at least one vaccine adjuvant, wherein said first antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1-3~~claim 1, wherein said first antibody has the same specificity of binding as that antibody defined in claim [4].
6. (Previously Presented) The pharmaceutical composition of claim 1, further comprising at least a second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.
7. (Previously Presented) The pharmaceutical composition of claim 1, wherein said first antibody is contained in a dosage range of 0.01 – 4 mg.
8. (Previously Presented) A method of treating cancer disease comprising administering to a patient in need thereof the pharmaceutical composition of claim 1.

Appl. No. 09/889,300

9. (Previously Presented) The method according to claim 8, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.
10. (Canceled)
11. (Cancelled)
12. (Currently Amended) The method of claim 8 or ~~10~~ wherein said first antibody is administered at a dosage in the range of 0.01 to 4 mg antibody.
13. (Canceled)
14. (Previously Presented) The method according to claim 12 wherein said dosage is 0.5 mg antibody.